{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:40Z","timestamp":1794255880275,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03687-0","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:29:18Z","timestamp":1786037358000},"page":"5430-5445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Dosing Patterns and Treatment Costs Among Patients with Spinal Muscular Atrophy Initiating Nusinersen and Risdiplam"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-497X","authenticated-orcid":false,"given":"Walter","family":"Toro Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Lemus Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"1","key":"3687_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"1","key":"3687_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Prim. 2022;8(1):52.","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"3687_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3687_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","volume":"178","author":"L Belter","year":"2024","unstructured":"Belter L, Taylor JL, Jorgensen E, et al. Newborn screening and birth prevalence for spinal muscular atrophy in the US. JAMA Pediatr. 2024;178(9):946\u20139.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"3687_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349.","journal-title":"J Child Neurol"},{"issue":"1","key":"3687_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Ann Rev Genomics Human Gen. 2020;21(1):231\u201361.","journal-title":"Ann Rev Genomics Human Gen"},{"issue":"10","key":"3687_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Dis. 2017;27(10):883\u20139.","journal-title":"Neuromuscul Dis"},{"issue":"1","key":"3687_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy type\u00a0I, II, and III in the United States. Orphanet J Rare Dis. 2017;12(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3687_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","volume":"46","author":"JA Markowitz","year":"2012","unstructured":"Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Ped Neurol. 2012;46(1):1\u201312.","journal-title":"Ped Neurol"},{"issue":"2","key":"3687_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157\u201367.","journal-title":"Muscle Nerve"},{"key":"3687_CR11","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: SPINRAZA (nusinersen). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf. Accessed 14 Aug 2025."},{"key":"3687_CR12","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: EVRYSDI (risdiplam). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. Accessed 11 Aug 2025."},{"key":"3687_CR13","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ZOLGENSMA (onasemnogene abeparvovec). https:\/\/www.fda.gov\/media\/126109\/download?attachment. Accessed 13 Aug 2025."},{"key":"3687_CR14","unstructured":"US Food and Drug Administration. ITVISMA\u00ae (onasemnogene abeparvovec-brve) suspension for intrathecal injection [Available from: https:\/\/www.fda.gov\/media\/189857\/download?attachment. Accessed 24 June 2026."},{"issue":"18","key":"3687_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"3687_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68(2):157\u201370.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3687_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase\u00a03 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3687_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase\u00a01 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341.","journal-title":"JAMA Neurol"},{"issue":"5","key":"3687_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of risdiplam in patients with type\u00a02 or non-ambulant type\u00a03 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346.","journal-title":"J Neurol"},{"issue":"1","key":"3687_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type\u00a02 and non-ambulant type\u00a03 spinal muscular atrophy (SUNFISH part 2): a phase\u00a03, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3687_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type\u00a01 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139.","journal-title":"Lancet Neurol"},{"key":"3687_CR22","unstructured":"CureSMA. State of SMA 2024. https:\/\/www.curesma.org\/wp-content\/uploads\/2025\/04\/State-of-SMA-Report2024_vWeb-4.pdf. Accessed 11 Aug 2025."},{"issue":"2","key":"3687_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais L, Day JW, De Vivo DC, et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Diseases. 2024;11(2):425\u201342.","journal-title":"J Neuromuscul Diseases"},{"key":"3687_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11101515","author":"D Krupa","year":"2023","unstructured":"Krupa D, Czech M, Chudzy\u0144ska E, Ko\u0144 B, Kostera-Pruszczyk A. Real world evidence on the effectiveness of nusinersen within the national program to treat spinal muscular atrophy in Poland. Healthcare. 2023. https:\/\/doi.org\/10.3390\/healthcare11101515.","journal-title":"Healthcare"},{"key":"3687_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102967","author":"MC Pera","year":"2016","unstructured":"Pera MC, Coratti G, Pane M, et al. Type\u00a0I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016. eClinicalMedicine. 2016. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102967.","journal-title":"eClinicalMedicine"},{"key":"3687_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S172291","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019. https:\/\/doi.org\/10.2147\/TCRM.S172291.","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"3687_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy\u2014insights and challenges in the treatment era. Nat Rev Neurol. 2020;16(12):706\u201315.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"3687_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D, et al. Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med. 2025;393(7):671\u201382.","journal-title":"N Engl J Med"},{"issue":"6","key":"3687_CR29","first-page":"540","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Ped. 2024;178(6):540\u20137.","journal-title":"JAMA Ped"},{"key":"3687_CR30","doi-asserted-by":"crossref","unstructured":"Gene therapy for spinal muscular atrophy: The benefit-cost profile. eClinicalMedicine. 2021;37:101065.","DOI":"10.1016\/j.eclinm.2021.101065"},{"issue":"1","key":"3687_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type\u00a01 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Market Access Health Policy. 2021;9(1):1889841.","journal-title":"J Market Access Health Policy"},{"key":"3687_CR32","unstructured":"R Core Team. 2023. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"3687_CR33","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38:5809\u201328.","journal-title":"Adv Ther"},{"issue":"7","key":"3687_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hach\u00e9","year":"2016","unstructured":"Hach\u00e9 M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31(7):899\u2013906.","journal-title":"J Child Neurol"},{"issue":"1","key":"3687_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03399-0","volume":"19","author":"A Patel","year":"2024","unstructured":"Patel A, Toro W, Yang M, et al. Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis. Orphanet J Rare Dis. 2024;19(1):494.","journal-title":"Orphanet J Rare Dis"},{"key":"3687_CR36","unstructured":"Iannaccone S, To T, Dickendesher T, Shapouri S, Pineda E. A retrospective analysis of adherence and persistence among risdiplam-treated patients with spinal muscular atrophy (SMA). Poster presented at the 2023 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 19\u201322 in Dallas, TX."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03687-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:34Z","timestamp":1794254614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3687"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03687-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Walter Toro Jimenez is an employee of Novartis Pharmaceuticals Corporation and holds stock\/options. Min Yang, Wei Song, Esteban Lemus Wirtz, and Dongni Ye are employees of Analysis Group, Inc., which has received consulting fees from Novartis Pharmaceuticals Corporation for the conduct of this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were de-identified and complied with the confidentiality requirements of the Health Insurance Portability and Accountability Act; therefore, no ethical review was required. This study was performed in accordance with the ethical principles of the Declaration of Helsinki of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}